Afluria Quadrivalent regulatory update

FDA approved an sBLA from CSL’s Seqirus unit for Afluria Quadrivalent to prevent infection from 2 influenza subtypes A and 2 influenza type B viruses contained in the vaccine in people ages >=18. Seqirus said Afluria Quadrivalent and Afluria will be available during the 2016-17 flu season. Both products are inactivated influenza vaccines; Afluria is approved to prevent infection from 2 influenza subtypes A and 1 influenza type B virus in people ages >=5. ...